ClinicalTrials.gg
CompletedNCT01709604PQUpdated Jun 14, 2016

Role of CVVH in Patients With Acute Paraquat Poisoning

An observational study in Poisoning by Paraquat With Undetermined Intent, sponsored by Ai Peng. Completed at 2 sites in China. Open to participants aged 14 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-06-14.

Sponsored by Ai Peng · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
110
Ages
14 Years to 70 Years
Sex
All
01

Study summary

Paraquat poisoning is characterized by multiple organ failure and pulmonary fibrosis with respiratory failure. Accumulating evidence suggested that continuous venovenous hemofiltration (CVVH) had a beneficial role in the treatment of multiple organ dysfunction. The investigators hypothesized that CVVH might restore multiple organ function and reduce the high mortality rate of paraquat poisoning. To confirm it, an prospective clinical study would be carried out.

Read the detailed description

Paraquat (1,1 '-dimethyl-4,4'-bipyridylium dichloride) is widely used as a herbicide. Accidental or intentional ingestion of paraquat is common in many developing countries such as China, Sri Lanka and Korea because of easy access. The high mortality rate of paraquat is due to its high toxicity and the lack of effective treatments. Thus, the paraquat poisoning becomes one of major medical problem in the developing countries.

Paraquat poisoning is also one of major causes of death among young patients with acute poisoning in China. It is characterized by multiple organ failure and pulmonary fibrosis with respiratory failure. A growing body of evidence suggested that continuous venovenous hemofiltration (CVVH) had a great beneficial role in the treatment of multiple organ dysfunctions. We hypothesized that CVVH might reduce the high mortality rate of paraquat poisoning via restoring the multiorgan function, such as acute hepatic lesion, acute kidney injury, acute lung injury and acute pancreatic injury. We expect to enroll 100 patients from our hospital within 1 week after oral intake of paraquat. All patients were divided into Group 1 and Group 2. Group 1 were treated with a standardized therapeutic regimen including stomach lavage, emergency haemoperfusion and drugs. Group 2 were accepted with standardized treatment plus CVVH. The aim of this prospective clinical study was to evaluate the safety and efficacy of CVVH for the treatment of patients with paraquat poisoning. The survival rate, clinical manifestations and clinical parameters between these two groups were compared.

02

Conditions studied

  • Poisoning by Paraquat With Undetermined Intent

Browse trials for

Keywords

  • acute paraquat poisoning
  • hemoperfusion
  • continuous blood purification
03

In context

Poisoning

98 studies on the registry are indexed under Poisoning; 16 are open to participants now.

This study's enrollment of 110 is close to the median of 122 across 41 observational studies indexed under Poisoning.

Browse Poisoning studies →

Lead sponsor

Ai Peng is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

In-patients with acute paraquat poisoning

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients recruited in this study should meet the requirements as follows:

    1. history of exposure to Paraquat
    2. concentration in urine or plasma from all patients who arrived at our hospital within 1 week of paraquat ingestion was more than 0.1 mg/L.
    3. Patients with a light blue, navy blue or dark blue color in urine dithionite tests within 1 week of PQ ingestion, were classified as having PQ intoxication and were included in this study.
    4. patients with acute organ dysfunction such as acute kidney injury, hepatic injury or pancreatic injury.

Exclusion criteria

Exclusion Criteria:

Patients who had colorless urine PQ tests, who arrived at any hospital more than 24 h after intoxication, who had not orally ingested PQ or any other drug poisonings, who were younger than 14 years or older than 70 years, or who had been included in any previous control trials were excluded.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
110 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • continuous venovenous hemofiltration

    Continuous venovenous hemofiltration(CVVH):blood access was achieved by placing a double lumen catheter in the femoral or internal jugular vein. Continuous diffusive solute transport is achieved by infusing a dialysis fluid that runs counter-current to blood at an ultrafiltration rate of 35 ml/h/Kg.

    Procedure: CVVH

  • Standardized therapy regimens

    The standardized therapy regimens included reduce absorption, accelerate the elimination and prevent the complications in patients with paraquat poisoning.

    Procedure: CVVH · Procedure: Standardized therapy regimens

Interventions

  • ProcedureCVVH

    Ultrafiltration at 35ml/h/Kg

    Also known as: continuous renal replacement treatment(CRRT), continuous blood purification(CBP)

  • ProcedureStandardized therapy regimens

    Standardized therapy regimens included the followings: 1. Remove all contaminated clothing 2. Gastric lavage 3. Receive activated charcoal as quickly as possible 4. Hemoperfusion with activated charcoal(160g) 5. Immunosuppression with methylprednisolone 6. Antioxidants (glutathione,1.2 gram iv twice a day) 7. Supportive care

06

What researchers measure

Primary outcomes

  1. Efficacy

    CVVH treatment efficacy was assessed by the following measurements: 1. Mortality rate: compared the difference between standardized therapy and CVVH treatment. 2. Number of organs involved in paraquat poisoning such as lung,kidney,liver and heart. 3. Degree of organ injuries 4. CT scan of lung 5. Biomarkers: 1)Oxidative stress: blood superoxide dismutase(SOD),malondialdehyde (MDA), superoxide dismutase (SOD), and catalase (CAT). 2)Proinflammatory factors: interleukins(IL-2,IL-6,IL-8 and IL-10) 3)Kidney function:serum cystatin C and estimated glomerular filtration rate (eGFR) and N-acetyl-β-(D)-glucosaminidase activity (NAG),kidney injury molecule-1 (KIM-1), Neutrophil gelatinase-associated lipocalin(NAGL) and urinary retinol-binding protein(RBP),etc. 4)Heart damage markers: cTnT,MYO,creatine kinase-MB(CK-MB) and brain natriuretic peptide(BNP).

    Time frame: at 6 months after paraquat poisoning

Secondary outcomes

  1. Safety of CVVH for the treatment of patients

    Safety and tolerability were assessed by the followings. 1. Changes from baseline in systolic blood pressure and mean artery pressure during CVVH treatment procedure. 2. Number of participants with adverse events such as bleeding, respiratory failure,hypotension,shock,thrombosis,pulmonary embolism and death.

    Time frame: at 2 weeks after paraquat poisoning

07

Study locations

2 sites
  • The division of nephrolgoy, Shanghai 10th people's hospital
    Shanghai, Shanghai 200072, China
  • The division of nephrology, Shanghai 10th people's hosptial
    Shanghai, Shanghai 200072, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2012
First posted
Oct 18, 2012
Start
Oct 2012
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Last update
Jun 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01709604
Lead sponsor
Ai Peng
Responsible party
Ai Peng (Director of the department of Nephrology, Shanghai 10th poeple's hospital, Shanghai 10th People's Hospital) — Sponsor-investigator
First posted
Oct 18, 2012
Start date
Oct 2012
Primary completion
Jun 2016
Completion
Jun 2016
Last update
Jun 14, 2016

Study contacts

Ai Peng, Ph.D., M.D.
principal investigator · Shanghai 10th People's Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion